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We contrast three types of abstinence: quit after alcohol associated problems (Q-AP), 
quit for other reasons (Q-OR), and lifetime abstainer (LTA). We summarized the 
characteristics of people living with HIV (PLWH), and matched uninfected individuals, by 
levels of alcohol use and types of abstinence. We then identified factors that differentiate 
abstinence and determined whether the association with an alcohol biomarker or a 
genetic polymorphism is improved by differentiating abstinence. Among abstainers, 34% 
of PLWH and 38% of uninfected were Q-AP; 53% and 53% were Q-OR; and 12% and 
10% were LTA. Logistic regression models found smoking, alcohol, cocaine, and 
hepatitis C increased odds of Q-AP, whereas smoking and marijuana decreased odds of 
LTA. Differentiating types of abstinence improved association. Q-APs and LTAs can be 
readily differentiated by an alcohol biomarker and genetic polymorphism. Differentiating 
type of abstinence may enhance understanding of alcohol health effects. 
   
 
 
















Harmful alcohol use, typically identified via diagnostic interview, is a world-wide 
problem which often goes unrecognized. Even when harmful use is recognized, 
treatments may be ineffective. New mechanistic insights from large-scale 
epidemiological, clinical, and genetic studies are needed to enable more effective 
recognition and treatment of this condition. However, due to the time and resources 
required, a diagnostic interview is impractical for use in large-scale studies. Further, 
while past patterns of alcohol consumption are well recognized among substance use 
researchers as an important independent predictor for many health outcomes(1, 2), 
alcohol exposure measures used in large scale epidemiologic and genetic studies often 
use state rather than lifetime (trait) measures, and therefore fail to consider patterns of 
past use that deviated from present use. 
Many large genetic studies of harmful alcohol use have employed International 
Classification of Disease diagnostic codes for Alcohol Use Disorder (AUD) codes(3-6) or 
the full or abbreviated Alcohol Use Disorders Identification Test (AUDIT)(7, 8), both of 
which have limitations. AUD codes are widely used to document diagnoses during 
clinical encounters. They are meant to reflect active conditions justifying treatment. 
However, codes are only recorded if present, making it impossible to differentiate 
patients who were screened and found not to have the diagnosis from those who were 
not screened. Further, AUD codes are insensitive and biased; for example, controlling 
for quantity-frequency data, African American ancestry is associated with a twofold 
increased risk of having an AUD code compared with European ancestry(9). The AUDIT 





alcohol-related problems over the past year(10). AUDIT-Consumption (AUDIT-C) 
consists of the first 3 questions, which measure the quantity and frequency of alcohol 
consumption and the frequency of heavy drinking over the past year(11, 12). In some 
healthcare systems, such as the Veterans Administration Healthcare System (VA), the 
AUDIT-C score is measured annually. However, as a self-reported metric, AUDIT-C is 
subject to social desirability bias(13), which may be more pronounced among individuals 
who have experienced alcohol-associated problems such as liver disease(14).   
Further, AUDIT-C measures only past-year consumption, a changeable state 
which may not encompass all those experiencing harm from alcohol. Most adults who 
report current abstinence drank in the past(15, 16), and some of these stopped due to 
problems associated with drinking. Few are lifelong abstainers. Many prior studies have 
demonstrated that failure to differentiate types of current abstinence based on prior 
drinking history likely diminishes statistical power and may contribute to biased 
results(17-23). Specifically, the often-reported u- or j-shaped association between level 
of alcohol consumption and cardiovascular disease may be confounded if the 
comparison group is comprised of abstinent individuals without regard to past drinking(2, 
24-26). Similarly, recently reported genetic correlations may be misleading(7, 8). 
However, to our knowledge, no study has directly considered the implications of this 
misclassification for genetic discovery. 
Some limitations of self-reported current state consumption measures such as 
AUDIT-C can be partially addressed using repeated measures. Using an average of 
seven AUDIT-C measures per participant, we demonstrated that long-term trajectories of 





abstinent and improved the association with a direct, shorter term (21 days), biomarker 
(phosphatidylethanol or PEth)(27). We also demonstrated stronger associations for 
AUDIT-C trajectories and age-adjusted mean AUDIT-C (AAM AUDIT-C) with 
polymorphisms of ADH1B among African Americans (AAs, rs2066702 or Arg369Cys)(9, 
27)  and European Americans (EAs, rs1229984 or Arg48His). This suggests that, while 
time frames of PEth and AUDIT-C are different, drinking patterns in middle age are 
comparatively stable and repeated longitudinal measures of self-report improve 
agreement with even a relatively short term (e.g. 21 days) biomarker. 
Accurate assessment of alcohol use among those living with HIV is particularly 
important since their greater physiologic frailty(28) and polypharmacy(29) likely makes 
them more susceptible to adverse effects of ongoing alcohol consumption, even at 
levels that may not be considered harmful among uninfected individuals(28). In many 
ways, a direct biomarker such as PEth, repeated over many years of observation might 
be an ideal metric. PEth is: only formed in the presence of alcohol; associated with 
alcohol exposure in a dose-response manner; and substantially more sensitive and 
specific than indirect measures of alcohol exposure such as carbohydrate deficient 
transferrin (CDT), gamma-glutamyltransferase (GGT), mean corpuscular volume (MCV), 
or aminotransferases (AST or ALT)(30). PEth can differentiate abstainers from moderate 
drinkers as well as identify severe alcohol misuse(31). Compared with using self-
reported AUDIT-C (>4), using a cutpoint of 250 ng/mL or more, PEth demonstrated a 
sensitivity of 87%, a specificity of 88%, a positive predictive value of 89% and a negative 
predictive value of 87%(31). Further, PEth is not subject to the issues of bias 





because it does not reflect past drinking beyond a 21-day interval. It would need to be 
repeated regularly to detect more widely spaced intervals of binge drinking. Further, 
PEth remains a “send out” test that can only be run by a few US laboratories with limited 
capacity, making large-scale longitudinal use of PEth impractical at present. 
Thus, using data from the Veterans Aging Cohort Study (VACS), a well-
characterized sample of people living with or without HIV that provides detailed self-
reported alcohol data and both PEth and genetic assays in the same subset, we 
identified three types of abstinence: former drinkers who quit after alcohol associated 
problems (Q-AP); former drinkers who quit for other reasons (Q-OR); and lifetime 
abstainer (LTA). Because people living with HIV infection (PLWH) are particularly 
susceptible to alcohol-associated health problems(28), we hypothesized that a greater 
proportion of PLWH would be Q-AP, compared to uninfected individuals. We first 
compared characteristics of individuals reporting different types of abstinence with 
individuals reporting recent use. We then considered factors that distinguish Q-APs and 
LTAs. Finally, we determined whether differentiating types of abstinence improves 
associations with PEth and, among African Americans in the cohort, with the ADH1B 




The Veterans Aging Cohort Study (VACS) survey sample is a cohort of PLWH 
and matched uninfected veterans consented for prospective, recurrent surveys on 





longitudinal VA electronic health record (EHR). The biomarker cohort is nested within the 
VACS survey sample and includes 1525 (69% AAs) PLWH and 843 (67% AAs) 
uninfected individuals who provided a blood sample in the period 2005-2007. 
Our analytic sample was restricted to VACS participants who completed a survey 
between October 2012 and February 2018. Data included demographics (age, sex, 
race/ethnicity [white, yes/no]), self-reported alcohol use and problems with alcohol, 
smoking status (never, current, and past) and drug use. Other conditions were based on 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
codes and laboratory results extracted from the EHR.  Our primary variable of interest 
was level of alcohol use according to AUDIT-C score and type of abstinence among 
those reporting abstinence (AUDIT-C=0).  Alcohol use was categorized as lifetime 
abstainer (defined as never having had a drink of alcohol), quit drinking (AUDIT-C=0, but 
reported past alcohol use), current non-hazardous (AUDIT-C 1-3), and current 
hazardous (AUDIT-C≥4)(12, 36). Problems with alcohol were based on the questions 
“Have you EVER had problems with alcohol?” (yes/no), and “Did you stop drinking 
because of these problems?” (yes/no).  
Other variables of interest included: Self-reported smoking based on 1) “Have you 
smoked at least 100 cigarettes (5 packs) in your entire life?”, 2) “How many cigarettes do 
you smoke per day NOW?”, 3) “How long has it been since you last smoked 
cigarettes?”, and if participant selected 4) “Have already quit”. Never smoker was based 
on answering no to smoking a least 100 cigarettes and having no indication of smoking, 
current smoker was based on questions 1, 2, and 3 – indication of smoking in the past 





days ago.  We were also interested in use of both current (in the past 12 months) and 
ever marijuana, cocaine, and heroin use based on “For each of the following drugs, 
please indicate how often in the 12 months you used each drug.”, 0=have never tried, 
1=no use in the last year, 2=less than once a month, 3=one to three times a month, 
4=one to three times a week, 5=four to six times a week, and 6=every day, where > 1 
was current use and >0 was ever. Alcohol use disorder and drug use disorder were 
based on ICD-9 codes; depression was based on the Primary Care Evaluation of Mental 
Disorders (PRIME-MD) survey items, where a score ≥ 10 is indicative of depression; and 
Hepatitis C (HCV) infection was based on ICD-9 code, a positive antibody titer, and/or 
detectable HCV RNA. The VACS index score 2.0, a validated measure of mortality risk 
and an indicator of severity of illness(37, 38), is composed of age, CD4 cell count, HIV-1 
RNA, hemoglobin, composite markers of liver and renal injury [Fibrosis-4 (FIB4) and 
estimated glomerular filtration rate (eGFR)], HCV infection status, albumin, white blood 
cell count, and body mass index.   
Analyses 
Characteristics were summarized across alcohol level and type of abstinence, by 
HIV status. Among individuals reporting abstinence, we evaluated factors associated 
with 1) Q-AP versus Q-OR and LTA and 2) LTA versus Q-AP and Q-OR using logistic 
regression. Model discrimination was assessed using the C-statistic, a measure 
comparable to area under the curve. Values range from 0.5 to 1.0, whereby C-statistic 
=1.0 denotes perfect discrimination.  
In the biomarker cohort, which is predominantly African American, we compared 





AUDIT-C scores, with and without stratification by type of abstinence (Q-AP, Q-OR, or 
LTA). We created AAM AUDIT-C using all AUDIT-C measures collected in the VA EHR 
from 2007-2016. Using age 50 years as the reference point, we created weights to 
down-weight scores for individuals younger than 50 and up-weight scores for individuals 
older than 50 years. This procedure has been described in detail(9). We calculated 
proportions with PEth>20 ng/ml (cutoff used for forensic work(27)), by AAM AUDIT-C 
score among the 1791 for whom a PEth assay was completed. Because the ADH1B 
polymorphism is common among individuals of African American ancestry (rs2066702 or 
Arg369Cys) we calculated the percentage of African Americans with the minor 369Cys 
allele by AAM AUDIT-C score among the 1380 individuals with genotype data. All 
statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, 
North Carolina, USA) and Stata 14.2. 
 
Results: 
Study Sample, Levels of Self-Reported Alcohol, and Type of Abstinence  
Among 4171 participants (2192 PLWH) the median age was 58 years (Table 1 a 
and b): 38% of PLWH versus 40% of uninfected reported abstinence (AUDIT-C=0, p= 
0.14); 41% of PLWH versus 34% of uninfected reported non-harmful use (AUDIT-C:1-3, 
p<0.001); and 21% of PLWH versus 25% of uninfected reported harmful use (AUDIT-C: 
4+, p=0.001). Of those reporting abstinence, 34% PLWH versus 38% uninfected were 
Q-AP; 53% versus 53% were Q-OR; and 12% versus 10% were LTA (p=0.19, 0.75, and 
0.14 respectively).   
After stratifying by age (Figure 1), the proportion of hazardous drinkers decreased 





While the overall proportion of LTAs remained relatively constant by age, the overall 
proportion of Q-APs increased with age from 6% among uninfected individuals <45 
years to 15% among PLWH who were 65+ years (p trend<0.001). The overall proportion 
of Q-ORs increased with age from 13% among uninfected individuals <45 years to 24% 
among PLWH who were 65+ years (p trend<0.001). 
When LTAs, Q-ORs, and Q-APs were compared using a trend test (Table 1 a and 
b), LTAs were least likely, and Q-APs were most likely, to have HCV infection (p<0.001), 
alcohol use disorder (p<0.001), drug use disorder (p<0.001), and depression (p=0.10 for 
PLWH and 0.001 for uninfected). Q-APs were also most likely to currently smoke or 




Among all patients reporting abstinence (810 PLWH, 716 uninfected), models 
accurately predicted Q-APs overall (Table 2, C-statistic: 0.71; 95% CI 0.68, 0.73) and 
stratified by HIV status (C-statistic: for PLWH 0.71; 95% CI 0.67, 0.74; for uninfected 
0.72; 95% CI 0.68, 0.76). In all models, current (overall OR 2.53; 95% CI 1.83, 3.48, 
PLWH OR 2.56; 95% CI 1.62, 4.02, and uninfected OR 2.54; 95% CI 1.60, 4.04; 
p<0.001 for all) and past (overall OR 2.85; 95% CI 2.07, 3.94, PLWH OR 2.82; 95% CI 
1.81, 4.40, and uninfected OR 3.04; 95% CI 1.89, 4.91; p<0.001 for all) smoking were 
the strongest predictors indicating a nearly 3-fold increased risk of being a Q-AP, 
compared to never smokers. Having an AUD code doubled the risk of Q-AP in all 
models. Among PLWH, HCV infection (OR 1.53; 95% CI 1.06, 2.19) and past cocaine 





cell count increased the odds of being a Q-AP (sqrt of CD4 OR 1.04; 95% CI 1.01, 1.07). 
Among uninfected individuals, past cocaine use (OR 1.79; 95% CI 1.06, 3.03) and AUD 
(OR 3.12; 95% CI 1.95, 4.97) were strong indicators of Q-AP.  
Models also accurately predicted LTAs overall (Table 3, C-statistic: 0.80; 95% CI 
0.77, 0.84) and by HIV status using the same variables as in models predicting Q-AP 
(Table 2). Models predicting LTAs showed largely opposite associations to those 
predicting Q-APs. For example, past (OR 0.14; 95% CI 0.09, 0.23) or current (OR 0.26; 
95% CI 0.16, 0.40) smokers were much less likely to be LTAs. LTAs were also unlikely 
to have used marijuana in the past (OR 0.39; 95% CI 0.23, 0.66).  
Except for white race being less common among LTAs (OR 0.45; 95% CI 0.26, 
0.78), demographic factors (age, sex, race/ethnicity) were not important indicators. 
Neither HIV status, VACS Index, nor depression were discriminating indicators for Q-AP 
or LTA membership. 
 
Association of PEth and ADH1B Polymorphism 
Among 1719 participants with AAM AUDIT-C scores and PEth assays, of which 
12% had PEth>20ng/ml, 750 (43.6%) cumulatively reported abstinence (AAM AUDIT-
C=0). Abstinent individuals sorted into the follow types: 58% Q-APs (n=435); 29% Q-
ORs (n=216); and 13% LTAs (n=99). Compared with using one overall abstinent group, 
differentiating types of abstinence (Figure 2) did not improve the strength of the 
statistical association of AAM AUDIT-C with PEth (p trend 2.79 X10-86 vs 3.20 x 10-79). 
Among the 1380 African American individuals with genotype data, 44% (n=610) reported 
cumulative abstinence (AAM AUDIT-C=0) and stratified into 58% (n=356) Q-APs, 28% 





differentiating type of abstinence (Figure 3) improved association of AAM AUDIT-C with 
rs 2066702 (p trend 0.03 vs 0.007). 
 
Discussion: 
Approximately 40% of adults in VACS, with or without HIV infection, report alcohol 
abstinence (AUDIT C=0) and, of these, 10% are Lifetime Abstainers (LTAs), a third are 
people who quit drinking after alcohol associated problems (Q-AP), and more than half 
are people who quit drinking for other reasons (Q-OR). LTAs were very distinct from Q-
APs. Among abstainers, multivariable logistic models demonstrated good discrimination 
(C-statistics ≥0.70) of Q-APs and LTAs. While differentiation of abstinence type did not 
statistically improve association with a short-term biomarker for alcohol exposure (PEth), 
it substantially increased the genetic trait association with the ADH1B polymorphism, 
which is protective against harmful alcohol use and is common among African 
Americans (rs2066702). Contrary to our hypothesis, PLWH were not more likely to 
report abstinence or to be Q-APs than uninfected comparators.  
Our work extends prior studies. Studies in the general population have long 
recognized the likelihood that some adults who quit drinking do so because of health 
problems(21, 22, 26, 39, 40) and this recognition led to including past alcohol use 
history(39), excluding individuals who endorse past alcohol use(22), or including in the 
comparison group only those who drink occasionally(23). None of these studies 
identified Q-APs or considered how they differed from Q-ORs. This is important because 
Q-APs and Q-ORs demonstrated different associations with PEth and with the genetic 





Among PLWH, Crane et al., using data from the Centers for AIDS Research 
Network of Integrated Clinical Systems (CNICS), found that 36% of those reporting 
current abstinence (AUDIT=0) had a prior AUD code(1).  Among those reporting 
abstinence, indicators of a prior AUD code included HCV coinfection and substance use. 
Unlike our analyses, these investigators had no means of identifying Q-APs. While AUD 
codes were an important indicator of Q-APs in our study, only a minority of Q-APs (24% 
PLWH, 43% of uninfected) had an AUD code. Further, we previously reported that 
controlling for AUDIT-C, African Americans are twice as likely to be given an AUD 
code(41), suggesting that AUD codes are assigned in a racially biased manner. A 
limitation which Q-AP, Q-OR, and LTA would not have. 
Importantly, we are not aware of any prior study demonstrating that differentiating 
Q-APs among abstainers increases the magnitude of the association with a genetic trait 
criterion standard. Given the need for innovative approaches to prevent and treat 
hazardous alcohol use and the difficulty in obtaining diagnostic interview data in large 
samples, our approach offers a way forward for enhanced genetic discovery. We are 
currently applying this approach in the Million Veteran Program(42). 
There were a few distinct patterns observed among PLWH. While PLWH were not 
more likely to report abstinence or to be Q-APs, PLWH were more likely to be infected 
with HCV, which was especially prevalent among Q-APs. Further, PLWH who were Q-
APs demonstrated higher CD4 cell counts and undetectable HIV-1 RNA, suggesting 
better access and adherence to antiretroviral therapy. Note, CD4 was an important 
indicator for Q-AP and HIV-1 RNA for LTA. PLWH who were Q-APs may have 
recognized that HIV infection is a serious illness in which close adherence to treatment 





Q-APs suggesting that those who endorsed having quit alcohol due to associated 
problems may be more invested in their health care. It would be interesting to see 
whether Q-APs are also more likely to adhere to treatments for diabetes or 
hypertension, but this is beyond the scope of the current study. 
It is particularly important that genetic studies conducted among middle-aged and 
older adults differentiate among abstainers to avoid misclassification. As expected, the 
proportion of LTAs remained relatively stable across ages. However, the proportion of Q-
ORs doubled and the proportion of Q-APs tripled from under 45 years of age to 65+ 
years. This was true among PLWH and uninfected. Further compounding potential 
misclassification, as witnessed by some PEth values greater than 20 ng/ml, some 
individuals who report abstinence continue to drink. Individuals with a medical reason 
not to drink (e.g., HCV infection) are more likely to report abstinence despite a positive 
PEth(14). Of note, Q-APs were three times as likely to have a PEth>20 ng/ml than LTAs 
and more than twice as likely as Q-ORs. 
Despite representing a largely middle-aged and older sample, large-scale genetic 
studies of hazardous alcohol use including UK Biobank(43), 23andMe(8), and the Million 
Veteran Program(42) have not differentiated among abstainers and have included them 
as controls. Dropping all individuals who report current abstinence from a genome-wide 
association study is certainly problematic as it entails the loss of one-quarter to one-half 
of the sample. Dropping these individuals omits LTAs and Q-ORs as well, both of whom 
may represent useful comparators; LTAs because they have chosen not to drink and Q-
ORs because they drank in the past without experiencing alcohol associated problems. 
As we demonstrate, it may be possible to identify likely Q-APs based upon available 





Assigning a probability of being a Q-AP among those reporting abstinence would allow 
them to be removed, statistically down weighted, or adjusted for as a confounder, 
preserving the use of those unlikely to be Q-APs as controls.  
Our failure to demonstrate an increased association with PEth likely reflects trait 
vs. state differences in the criterion standards employed. ADH1B genotype is a trait, 
while PEth reflects alcohol use in the past 21 days and is a changeable state. In fact, the 
calendar period over which AAM AUDIT-C was estimated preceded the 21-day window 
for the PEth assay. We included these results because they suggest that self-reported 
alcohol use may be differentially inaccurate by abstainer group. Specifically, people who 
report abstinence, particularly Q-APs, may be more likely to currently drink. It is 
noteworthy that the VACS Index was not associated with type of abstinence. This 
suggests that being a Q-AP has more to do with psychosocial problems from alcohol 
and related substance use or specific health problems such as liver disease than with 
the overall physiologic frailty measured by the VACS Index(28, 29, 44). 
Our analyses have important strengths. Data on alcohol and other substance use 
were collected in several ways, allowing us to compare AUDIT-C survey responses with 
alcohol use disorder and other indicators of substance use both from self-reported 
surveys and the electronic health record. We consider comorbid physical and mental 
health conditions and look at associations with two criterion standards for alcohol (PEth 
and the ADH1B minor allele frequency). We were also able to consider genetic 
associations among African American ancestry, a substantially under studied group.  
Our study also has limitations. We were not able to differentiate current 
abstainers according to when they last drank regularly. Further, self-reported alcohol 







In conclusion, despite being grouped together in most genetic studies of alcohol, 
not all those reporting current abstinence are alike and what determines membership in 
these groups is largely consistent by HIV status. Q-APs are distinct from LTAs in 
predictable ways. Treating individuals who report abstinence as a single group likely 
causes misclassification and confounding, weakening associations, especially among 
middle-aged and older adults. Omitting all abstinent individuals would be associated with 
a dramatic reduction in sample size and loss of important comparator groups. As an 
alternative, it may be possible to probabilistically identify likely Q-APs among those 
reporting abstinence. Investigators might then censor, down weight, or control for these 
observations, minimizing misclassification and confounding, maintaining sample size 
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Table 1a. Characteristics by Current Alcohol Use among People Living with HIV 
 
 People Living with HIV 
 Current Abstinence (AUDIT C = 0) Non-Hazardous 
AUDIT C 1-3 
Hazardous  
AUDIT C 4+ % LTA Q-OR Q-AP p trend 
n 102 445 288  -- 894 463 
Age, mean (SD) 57 (10) 59 (8) 59 (7) 0.11 56 (10) 56 (10) 
Black 75 64 68 0.67 67 71 
Hispanic 13 10 9 0.40 8 10 
White 8 19 15 0.57 20 14 
Male 99 97 97 0.42 97 98 
Hepatitis C 22 36 50 <0.001 26 31 
Alcohol use disorder  6 11 24 <0.001 10 22 
Drug use disorder 9 20 31 <0.001 19 24 
Depression 19 17 24 0.10 16 20 
Past marijuana  25 47 57 <0.001 41 38 
Current marijuana  10 14 13 0.55 31 43 
Past cocaine  21 37 54 <0.001 34 35 
Current cocaine  6 7 7 0.63 12 30 
Past heroin  16 20 39 <0.001 16 23 
Current heroin  3 3 3 0.71 4 5 
Current smoker  22 33 40 <0.001 38 57 
Past smoker 15 38 46 <0.001 27 20 
VACS index 2.0, IQR 46 (36, 58) 49 (39, 62) 48 (41, 62) 0.21 46 (35, 58) 48 (38, 61) 
CD4, IQR 516 (330, 728) 532 (344, 741) 554 (399, 789) 0.10 532 (353, 707) 478 (315, 694) 
Viral Load ≤75 copies/mL 76 84 84 0.18 79 71 
  
Column % are reported unless otherwise specified. IQR – interquartile range, FIB4 – Fibrosis-4 score, Q-AP – Quit after alcohol 
associated problems, Q-OR – Quit for other reasons, LTA – Lifetime Abstainer 
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Table 1b. Characteristics by Current Alcohol Use among Uninfected 
 
 Uninfected 
 Current Abstinence (AUDIT C = 0) Non-Hazardous 
 AUDIT C 1-3 
Hazardous 
AUDIT C 4+ % LTA Q-OR Q-AP p trend 
n 79 419 300 --  679 502 
Age, mean (SD) 60 (9) 60 (10) 59 (8) 0.21 57 (10) 55 (11) 
Black 76 68 67 0.25 66 65 
Hispanic 9 11 10 0.81 10 13 
White 13 16 18 0.24 18 16 
Male 89 90 96 0.002 92 97 
Hepatitis C 18 25 35 0.0004 17 20 
Alcohol use disorder  14 22 43 <0.001 29 52 
Drug use disorder  27 37 49 <0.001 38 49 
Depression 10 19 26 0.001 20 27 
Past marijuana  19 42 55 <0.001 42 44 
Current marijuana  9 13 12 0.63 24 33 
Past cocaine  15 35 51 <0.001 30 35 
Current cocaine  5 9 12 0.06 20 28 
Past heroin  9 25 37 <0.001 16 21 
Current heroin  4 5 4 0.95 6 5 
Current smoker  18 40 47 <0.001 48 66 
Past smoker 11 32 38 <0.001 22 17 
VACS index 2.0, IQR 36 (30, 45) 38 (30, 47) 37 (30, 45) 0.75 34 (27, 42) 34 (27, 43) 
 
   Column % are reported unless otherwise specified. IQR – interquartile range, FIB4 – Fibrosis-4 score, Q-AP – Quit drinking after alcohol   






Table 2. Among 1526 Reporting Abstinence (AUDIT-C=0) Indicators of Quit Drinking After Alcohol Associated Problems 
(Q-AP) from Multivariable Logistic Regression. 
 
  Overall, n=1526 PLWH, n=810 Uninfected, n=716 
Variables OR (95 %CI) p value OR (95 %CI) p value OR (95 %CI) p value 
Age per 10yrs increment 0.94 (0.80, 1.11) 0.48 0.92 (0.72, 1.18) 0.51 0.90 (0.69, 1.17) 0.42 
Female vs. male 0.69 (0.39, 1.25) 0.22 1.38 (0.51, 3.73) 0.53 0.48 (0.23, 1.02) 0.06 
White non-Hispanic 1.20 (0.89, 1.63) 0.24 1.07 (0.69, 1.66) 0.76 1.39 (0.90, 2.15) 0.13 
Hepatitis C 1.51 (1.16, 1.96) 0.002 1.53 (1.06, 2.19) 0.02 1.42 (0.93, 2.16) 0.10 
Current smoker vs. never 2.53 (1.83, 3.48) <0.001 2.56 (1.62, 4.02) <0.001 2.54 (1.60, 4.04) <0.001 
Past smoker vs. never 2.85 (2.07, 3.94) <0.001 2.82 (1.81, 4.40) <0.001 3.04 (1.89, 4.91) <0.001 
Depression 1.25 (0.94, 1.65) 0.12 1.24 (0.84, 1.83) 0.28 1.24 (0.83, 1.87) 0.30 
Current cocaine use 1.39 (0.87, 2.22) 0.17 1.28 (0.64, 2.55) 0.49 1.58 (0.82, 3.05) 0.17 
Past cocaine use 1.76 (1.27, 2.44) 0.001 1.74 (1.13, 2.66) 0.01 1.79 (1.06, 3.03) 0.03 
Current marijuana use 0.87 (0.58, 1.30) 0.49 0.97 (0.56, 1.69) 0.93 0.78 (0.42, 1.44) 0.42 
Past marijuana use 1.06 (0.77, 1.48) 0.71 1.11 (0.72, 1.74) 0.63 1.07 (0.64, 1.77) 0.81 
Alcohol use disorder  2.73 (1.93, 3.84) <0.001 2.30 (1.36, 3.89) 0.002 3.12 (1.95, 4.97) <0.001 
Drug use disorder 0.76 (0.55, 1.05) 0.10 0.98 (0.62, 1.55) 0.92 0.59 (0.37, 0.96) 0.03 
VACS index 2.0 by 5 0.98 (0.93, 1.03) 0.37 1.03 (0.96, 1.11) 0.35 0.94 (0.86, 1.04) 0.22 
HIV 0.95 (0.73, 1.24) 0.72         
CD4*     1.04 (1.01, 1.07) 0.01     
Viral Load ≤75 copies/mL     1.11 (0.68, 1.81) 0.68     
C Statistics (95% CI) 0.71 (0.68, 0.73) 0.71(0.67, 0.74) 0.72 (0.68, 0.76) 
 






Table 3. Among 1526 Reporting Current Abstinence (AUDIT-C=0) Indicators of Being a Lifetime Abstainer (LTA) 
 
  Overall, n=1526 PLWH, n=810 Uninfected, n=716 
Variables OR (95 %CI) p value OR (95 %CI) p value OR (95 %CI) p value 
Age per 10yrs increment 0.97 (0.78, 1.20) 0.76 1.12 (0.81, 1.53) 0.50 0.98 (0.69, 1.40) 0.92 
Female vs. male 0.69 (0.33, 1.47) 0.33 0.24 (0.03, 1.88) 0.17 1.00 (0.42, 2.38) 1.00 
White non-Hispanic 0.45 (0.26, 0.78) 0.005 0.35 (0.16, 0.77) 0.01 0.61 (0.27, 1.34) 0.22 
Hepatitis C 0.66 (0.41, 1.05) 0.08 0.65 (0.35, 1.21) 0.18 0.92 (0.41, 2.05) 0.83 
Current smoker vs. never 0.26 (0.16, 0.40) <0.001 0.32 (0.18, 0.57) 0.0001 0.18 (0.09, 0.36) <0.001 
Past smoker vs. never 0.14 (0.09, 0.23) <0.001 0.17 (0.09, 0.32) <0.001 0.11 (0.05, 0.24) <0.001 
Depression 0.96 (0.60, 1.55) 0.87 1.12 (0.62, 2.04) 0.71 0.73 (0.32, 1.66) 0.45 
Current cocaine use 0.86 (0.38, 1.97) 0.72 1.17 (0.37, 3.66) 0.79 0.53 (0.15, 1.87) 0.33 
Past cocaine use 0.82 (0.46, 1.47) 0.50 0.92 (0.45, 1.87) 0.82 0.62 (0.22, 1.72) 0.36 
Current marijuana use 0.62 (0.33, 1.18) 0.15 0.47 (0.20, 1.11) 0.08 0.93 (0.35, 2.48) 0.88 
Past marijuana use 0.39 (0.23, 0.66) 0.0004 0.37 (0.19, 0.71) 0.003 0.38 (0.16, 0.91) 0.03 
Alcohol use disorder  0.52 (0.26, 1.06) 0.07 0.70 (0.23, 2.12) 0.53 0.45 (0.18, 1.12) 0.09 
Drug use disorder 0.86 (0.47, 1.55) 0.61 0.52 (0.20, 1.34) 0.18 1.39 (0.61, 3.18) 0.43 
VACS index 2.0 by 5 1.02 (0.95, 1.10) 0.56 0.93 (0.83, 1.05) 0.24 1.07 (0.92, 1.25) 0.40 
HIV 1.07 (0.71, 1.62) 0.75         
CD4*     0.97 (0.93, 1.02) 0.22     
Viral Load ≤75 copies/mL     0.52 (0.26, 1.03)   0.06     
C Statistics (95% CI) 0.80 (0.77, 0.84) 0.81(0.76, 0.85) 0.82 (0.77, 0.87) 
  





Figure 1. Current Alcohol Use by Age and HIV Status 
 
PLHW – people living with HIV 
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Figure 2. Percent with PEth>20 ng/ml by AAM AUDIT-C and Abstainer Type 
 




Figure 3. Percent with ADH1B rs2066702 Minor Allele by AAM AUDIT-C and Abstainer Type 
 
  P for trend across all 6-levels, p = 0.0034; across the 4-levels of AUDIT-C=0, p = 0.018 
